Dr. Timothy Shannon is Chairman of the Board of Arvinas and a Venture Partner at Canaan Partners. He also serves on the boards of Canaan portfolio companies IDEAYA Biosciences, Nextcure, Spyryx Biosciences, Vivace Therapeutics, and VaxInnate Corporation.
Previously, Dr. Shannon was President and Chief Executive Officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as Executive Vice President of R&D and Chief Medical Officer. He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group, including Senior Vice President of Global Medical Development. Prior to his career in industry, Dr. Shannon was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine.
Dr. Shannon received his B.A. in Chemistry from Amherst College, his medical degree from the University of Connecticut, and completed his postgraduate medical training at the Beth Israel Hospital of Harvard Medical School and Boston University.
